Pancreatic Cancer Research

ResearcherNihon UniversityActive in the last 2 years

Yoshimi Ichimaru

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-1290-0500; OpenAlex author ID A5050514594. Sources: OpenAlex.

Their work

Papers
7 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
16
Papers, trials and grants by year

2017: 1 paper · 2018: none · 2019: 1 paper · 2020: 1 paper · 2021: none · 2022: 1 paper · 2023: 1 paper · 2024: 1 paper · 2025: none · 2026: 1 paper

Papers 7

  1. Blocking L-carnitine synthesis by meldonium prolongs the survival in mice with pancreatic cancer. Co-author DOI 10.1016/j.isci.2026.117071↗
  2. Effects of tramadol via a µ-opioid receptor on pancreatic ductal adenocarcinoma in vitro and in vivo. Co-author DOI 10.1136/rapm-2023-104511↗
  3. Mirogabalin improves cancer-associated pain but increases the risk of malignancy in mice with pancreatic cancer. Co-author DOI 10.1097/j.pain.0000000000002852↗
  4. Midazolam exhibits antitumour and anti-inflammatory effects in a mouse model of pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.bja.2021.12.042↗
  5. Duloxetine improves cancer-associated pain in a mouse model of pancreatic cancer through stimulation of noradrenaline pathway and its antitumor effects. Co-author DOI 10.1097/j.pain.0000000000001997↗
  6. Indirubin 3'-Oxime Inhibits Migration, Invasion, and Metastasis InVivo in Mice Bearing Spontaneously Occurring Pancreatic Cancer via Blocking the RAF/ERK, AKT,… Co-author DOI 10.1016/j.tranon.2019.08.010↗
  7. Induction of cell death in pancreatic ductal adenocarcinoma by indirubin 3'-oxime and 5-methoxyindirubin 3'-oxime in vitro and in vivo. First author DOI 10.1016/j.canlet.2017.03.031↗

Closest collaborators

The 16 strongest of 16 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Makoto Sano · 7 shared papers, 2017–2026 · strength 1.01
  2. Hideaki Ijichi · 6 shared papers, 2019–2026 · strength 0.95
  3. Atsushi Masamune · 5 shared papers, 2020–2026 · strength 0.85
  4. Ichie Kajiwara · 5 shared papers, 2019–2024 · strength 0.71
  5. Takahiro Suzuki · 4 shared papers, 2020–2024 · strength 0.61
  6. Yukino Oshima · 4 shared papers, 2020–2024 · strength 0.61
  7. Tomoaki Itaya · 3 shared papers, 2022–2024 · strength 0.50
  8. Tomoya Kuramochi · 3 shared papers, 2022–2024 · strength 0.50
  9. Yohei Masugi · 2 shared papers, 2022–2026 · strength 0.38
  10. Akiyoshi Hirayama · 1 shared paper, 2026 · strength 0.24
  11. Koji Miyabayashi · 1 shared paper, 2026 · strength 0.24
  12. Gen Kimura · 1 shared paper, 2026 · strength 0.24
  13. Mitsuhiro Fujishiro · 1 shared paper, 2026 · strength 0.24
  14. Hiroyuki Hao · 2 shared papers, 2017–2020 · strength 0.17
  15. Shinichi Miyairi · 2 shared papers, 2017–2019 · strength 0.16
  16. Hiroki Yoshioka · 1 shared paper, 2019 · strength 0.10

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.